» Articles » PMID: 29136944

MIAT Promotes Proliferation and Hinders Apoptosis by Modulating MiR-181b/STAT3 Axis in Ox-LDL-induced Atherosclerosis Cell Models

Overview
Date 2017 Nov 16
PMID 29136944
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Plenty of lncRNAs and microRNAs have been identified to be critical mediators in the progression of atherosclerosis (AS). Myocardial infarction-associated transcript (MIAT) were aberrantly high expressed and closely associated with the pathogenesis of AS. However, its molecular mechanism has not been well characterized.

Methods: The expression patterns of MIAT and microRNA-181b (miR-181b) in clinical samples and cells were measured by RT-qPCR assays. Luciferase reporter assay and RIP assays were used to manifest the potential interaction between MIAT, miR-181b and signal transducer and activator of transcription 3 (STAT3). Cell Counting Kit-8 (CCK-8), Propidium Iodide (PI) staining, Terminal dexynucleotidyl transferase(TdT)-mediated dUTP nick end labeling (TUNEL) and western blot assays were carried out to detect cell proliferation, cell cycle distribution, apoptosis, and STAT3 protein level, respectively.

Results: MIAT expression was up-regulated and miR-181b expression was down-regulated in AS patients serum and oxidized low-density lipoprotein (ox-LDL) induced AS cells model. MIAT facilitated cell proliferation, accelerated cell cycle progression and inhibited apoptosis in ox-LDL-induced AS cell lines, while this effect was partly reversed by miR-181b overexpression. Moreover, MIAT enhanced STAT3 expression through sequestering miR-181b as a molecular sponge. Furthermore, MiR-181b hindered cell growth, induced cell cycle arrest and promoted apoptosis by directly targeting STAT3.

Conclusion: MIAT performed as an induction factor of AS by regulating miR-181b/STAT3 axis in ox-LDL-induced AS cell lines, offering a new insight into the potential application of MIAT in AS treatment.

Citing Articles

MicroRNA-181 in cardiovascular disease: Emerging biomarkers and therapeutic targets.

Lv B, He S, Li P, Jiang S, Li D, Lin J FASEB J. 2024; 38(9):e23635.

PMID: 38690685 PMC: 11068116. DOI: 10.1096/fj.202400306R.


Inhibition of lncRNA NFIA-AS1 Alleviates Abnormal Proliferation and Inflammation of Vascular Smooth Muscle Cells in Atherosclerosis by Regulating miR-125a-3p/AKT1 Axis.

Zhu Y, Tian X, Wang Y, Wang C, Yang N, Ying L Int J Genomics. 2023; 2023:8437898.

PMID: 37056786 PMC: 10089782. DOI: 10.1155/2023/8437898.


Vascular mechanotransduction.

Davis M, Earley S, Li Y, Chien S Physiol Rev. 2023; 103(2):1247-1421.

PMID: 36603156 PMC: 9942936. DOI: 10.1152/physrev.00053.2021.


Non-Coding RNAs in Regulating Plaque Progression and Remodeling of Extracellular Matrix in Atherosclerosis.

Singh D, Rai V, Agrawal D Int J Mol Sci. 2022; 23(22).

PMID: 36430208 PMC: 9692922. DOI: 10.3390/ijms232213731.


Dirty Jobs: Macrophages at the Heart of Cardiovascular Disease.

Stevens T, Khalaf F, Soehnlen S, Hegde P, Storm K, Meenakshisundaram C Biomedicines. 2022; 10(7).

PMID: 35884884 PMC: 9312498. DOI: 10.3390/biomedicines10071579.